These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 15324384

  • 1. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW, Goh KL.
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [Abstract] [Full Text] [Related]

  • 2. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW, Goh KL, Wong BC.
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [Abstract] [Full Text] [Related]

  • 3. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD, Ducrotté P, Vallot T.
    Presse Med; 2004 Jun 19; 33(11):746-54. PubMed ID: 15257232
    [Abstract] [Full Text] [Related]

  • 4. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON, Maslovskiĭ LV, Anikina NIu, Shuleshova AG.
    Eksp Klin Gastroenterol; 2005 Jun 19; (2):29-35. PubMed ID: 15932152
    [No Abstract] [Full Text] [Related]

  • 5. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J.
    Am J Gastroenterol; 2000 Nov 19; 95(11):3081-8. PubMed ID: 11095321
    [Abstract] [Full Text] [Related]

  • 6. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
    Miner P.
    Aliment Pharmacol Ther; 2004 Nov 19; 20 Suppl 6():20-9. PubMed ID: 15496215
    [Abstract] [Full Text] [Related]

  • 7. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov 19; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 8. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI, Zhikhareva NS, Rachkova NS, Babaian ML, Volynets GV, Khanakaeva ZK.
    Eksp Klin Gastroenterol; 2004 Nov 19; (2):53-6. PubMed ID: 15462323
    [No Abstract] [Full Text] [Related]

  • 9. Rabeprazole.
    Med Lett Drugs Ther; 1999 Nov 19; 41(1066):110-2. PubMed ID: 10987010
    [No Abstract] [Full Text] [Related]

  • 10. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul 19; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F, Bardhan KD, Perdomo C, Niecestro R, Barth J.
    Dig Dis Sci; 2001 Mar 19; 46(3):587-96. PubMed ID: 11318537
    [Abstract] [Full Text] [Related]

  • 12. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J, Dodd S, Durkin M, Sloan S.
    Manag Care; 2002 Jul 19; 11(7 Suppl):14-8. PubMed ID: 12181872
    [Abstract] [Full Text] [Related]

  • 13. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 14. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M.
    Aliment Pharmacol Ther; 2004 Nov 01; 20 Suppl 6():30-7. PubMed ID: 15496216
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacogenomical aspects of gastroesophageal reflux disease].
    Isaev VA.
    Vestn Ross Akad Med Nauk; 2005 Nov 01; (6):33-6. PubMed ID: 16022110
    [Abstract] [Full Text] [Related]

  • 16. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
    Robinson M.
    Int J Clin Pract; 2005 Jun 01; 59(6):709-15. PubMed ID: 15924600
    [Abstract] [Full Text] [Related]

  • 17. Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.
    Hong SP, Park PW, Hwang SG, Ko KH, Kwak SY, Kim SH, Kwon KS, Shin YW, Ryu JK, Ryu KH, Park SJ, Won WH, Yoo HM, Bae HM, Park MJ, Woo YK, Kim KC, Kim KH, Na SH, Kim JW.
    Korean J Intern Med; 2004 Jun 01; 19(2):93-8. PubMed ID: 15366639
    [Abstract] [Full Text] [Related]

  • 18. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH, Ke MY, Song ZQ, Luo JY, Yuan YZ, Hou XH, Zhu YL, Sun J, Zha H.
    Zhonghua Nei Ke Za Zhi; 2005 Nov 01; 44(11):818-21. PubMed ID: 16316559
    [Abstract] [Full Text] [Related]

  • 19. Optimizing acid-suppression therapy.
    Barnett JL, Robinson M.
    Manag Care; 2001 Oct 01; 10(10 Suppl):17-21. PubMed ID: 11729443
    [Abstract] [Full Text] [Related]

  • 20. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML, Enas N, Humphries TJ, Bassion S.
    Dig Dis Sci; 1998 May 01; 43(5):993-1000. PubMed ID: 9590413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.